Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bioavailability of Spesolimab SC Delivery Modes
NCT06520514Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of spesolimab in generalized pustular psoriasis (GPP) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event. Started Aug 2024; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06520514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520514.